<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00393042</url>
  </required_header>
  <id_info>
    <org_study_id>CRIT124E US15</org_study_id>
    <secondary_id>2006-0423</secondary_id>
    <secondary_id>2006-04</secondary_id>
    <nct_id>NCT00393042</nct_id>
  </id_info>
  <brief_title>Sleep and Tolerability Study: Comparing the Effects of Adderall XR and Focalin XR</brief_title>
  <official_title>Sleep and Tolerability of Extended Release Dexmethylphenidate vs. Mixed Amphetamine Salts: A Double Blind, Placebo Controlled Study (SAT STUDY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seattle Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate how children and adolescents with Attention Deficit/
      Hyperactivity Disorder (ADHD) respond to treatment with three differing doses of stimulant
      medications used to treat ADHD, Adderall XR® and Focalin XR®. Another purpose of the study is
      to evaluate if there are differences in sleep and other side effects, such as changes in mood
      or loss of appetite, which can occur with stimulant medications. A third purpose is to
      determine if there are differences in the characteristics of individuals who respond better
      to either of the medications.

      This research is being done because the investigators do not know if one of these two
      commonly used treatments is better tolerated than the other. Children and adolescents with
      ADHD often have a hard time sitting still, playing quietly, finishing things they start,
      paying attention, waiting their turn, and not distracting others. These medications improve
      these symptoms, but sometimes affect sleep, appetite, or mood.

      It is hypothesized that at effective and frequently prescribed doses, Adderall will be
      associated with insomnia, more stimulant side effects, and decreased tolerability during an
      acute trial relative to Focalin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADHD is often treated with stimulant medications, which have demonstrated short-term efficacy
      in numerous trials. However, treatment is often discontinued prematurely. Although ADHD often
      persists through adolescence, approximately half of all children who are treated with a
      stimulant medication discontinue treatment within one year (Charach, Ickowicz et al. 2004).
      Presumably, tolerability and treatment compliance are highly related to the side effect
      profile of stimulant medications (Schachar, Jadad et al. 2002). Sleep problems, particularly
      insomnia, are frequently associated with ADHD and are often exacerbated by stimulant
      medications, particularly at higher doses. Other frequent stimulant side effects are
      decreased appetite and mood lability (dysphoria/euphoria). Little is known about the relative
      effects of different stimulant formulations and dosages (i.e amphetamine, methylphenidate,
      dexmethylphenidate) on sleep and tolerability. There is some preliminary data with short
      acting stimulants suggesting a higher prevalence of sleep and appetite problems with
      amphetamine relative to mph (Pelham, Aronoff et al. 1999). Several studies indicate that
      sleep and other stimulant side effects are dose related (Stein, Sarampote et al. 2003),
      although this has not been found in all studies. Moreover, it is unclear if there are
      differences between long-acting amphetamine and methylphenidate based stimulants in their
      side effect profile and tolerability. Thus, we will directly compare these two long acting
      stimulant medications on their side effect profile and tolerability, including measures of
      sleep, mood, and evening behavior (e.g., family conflicts). The recently developed extended
      release formulation of dexmethylphenidate will be compared to one of the most common
      treatments for ADHD, extended release formulation of mixed amphetamine salts. The subject
      population will be older children and adolescents (10-17) with ADHD who are most likely to be
      treated with moderate to higher dose levels of stimulant medications and can complete all
      self-report measures.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleep Start Time, and End Time as Determined by Actigraph and Sleep Diary Over 8 Weeks.</measure>
    <time_frame>8-10 weeks</time_frame>
    <description>Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep. The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Duration</measure>
    <time_frame>8-10 weeks</time_frame>
    <description>Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep.The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ADHD Parent Rating Scale-IV</measure>
    <time_frame>completed weekly over 8-10 weeks</time_frame>
    <description>Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dopamine Active Transporter (DAT) 1 Gene Type Effects on ADHD Symptoms</measure>
    <time_frame>8-10 weeks</time_frame>
    <description>Three variations of the DAT 1 gene were observed, the 9/9 allele, the 9/10 allele and the 10/10 allele. The ADHD Rating Scale (ADHD-RS) and Clinical Global Impressions - Severity (CGI-S) measures were used to evaluate how the DAT 1 gene allele type altered the efficacy of the medication. The DAT 1 genotype did not predict differential response to Focalin XR or Adderall XR so the dose levels of each drug was combined to examine how the genotype interacted with the dose level. The ADHD-RS evaluates the severity of the participant's ADHD symptoms and includes two subscales: Inattention and Hyperactivity/Impulsivity. Both subscale scores range from 0 to 27 with a higher score representing more severe symptoms. The subscales are summed to calculate the total score which can range from 0 to 54. The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Severity</measure>
    <time_frame>8-10 weeks</time_frame>
    <description>The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weiss Functional Impairment Rating Scale (WFIRS)</measure>
    <time_frame>8-10 weeks</time_frame>
    <description>The WFIRS consists of 50 questions where respondents are asked to rate their child's functional impairment. The items of the WFIRS are scored on a four point Likert-type rating scale: 0 (never or not at all), 1 (sometimes or somewhat), 2 (often or much) or 3 (very often or very much) and aggregated to produce six domain scores: Family (ranges between 0-24), Learning or School (ranges between 0-33), Self-Concept (ranges between 0-15), Social Activities (ranges between 0-27), Life Skills (ranges between 0-36), and Risky Activities (ranges between 0-42). The subscales are scored by summing the responses in the subsection. The Total score is the sum of all the responses and it ranges between 0-150. The higher the score in each of the subscales the more impairment is recorded, this is also true for the total score.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Attention Deficit Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Focalin XR then Adderall XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are given the Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week followed by Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall XR then Focalin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects are given the Adderall XR (mixed amphetamine salts) for four weeks with a randomized placebo week followed by Focalin XR first (dexmethylphenidate) for four weeks with a randomized placebo week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmethylphenidate</intervention_name>
    <description>10, 20, 25-30 mg.</description>
    <arm_group_label>Focalin XR then Adderall XR</arm_group_label>
    <arm_group_label>Adderall XR then Focalin XR</arm_group_label>
    <other_name>Focalin XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mixed Amphetamine Salts, ER</intervention_name>
    <description>10, 20, 25-30</description>
    <arm_group_label>Focalin XR then Adderall XR</arm_group_label>
    <arm_group_label>Adderall XR then Focalin XR</arm_group_label>
    <other_name>Adderall XR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>randomized placebo week during each 4 week period</description>
    <arm_group_label>Focalin XR then Adderall XR</arm_group_label>
    <arm_group_label>Adderall XR then Focalin XR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Any ADHD subtype, determined by KSADS interview (Kaufman, Birmaher et al. 1997).
             Comorbidity will likewise be allowed, to ensure representation.

          -  Signed informed consent and assent

          -  Clinical Global Impressions - Severity for ADHD (CGI-S-ADHD) rating is greater than or
             equal to 4

          -  Findings on physical exam, laboratory studies, vital signs, and ECG are judged to be
             normal for age

          -  Pulse and blood pressure are within 95% of age and gender mean

          -  Able to complete study instruments and swallow capsules

          -  Willing to commit to the entire visit schedule for the study, including at least one
             visit to UIC Medical Center.

        Exclusion Criteria:

          -  Previous diagnosis of mental retardation

          -  Non-responder to either medication at the doses offered in the study in an adequate
             trial

          -  Must not have experienced disabling adverse effects with either medication

          -  Concomitant psychotropic medications are required or medications which might have a
             CNS effect

          -  Any other medical condition which represents a contraindication for either treatment
             is present

          -  History of alcohol or drug abuse in the past 3 months, or a positive urinary toxic
             screen on initial evaluation that is not explained by a time-limited medical
             circumstance

          -  Females of childbearing age who are sexually active, do not use acceptable birth
             control (double protection method), and after counseling, are unwilling to do so

          -  History of allergic reactions to multiple medications

          -  A history of psychosis

          -  Diagnosis of bipolar disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark A Stein, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois-Chicago; Hyperactivity, Attention and Learning Problems Clinic (HALP)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Charney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois-Chicago, Hyperactivity, Attention, and Learning Problems Clinic (HALP)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northbrook HALP Clinic/ADHD Research Center</name>
      <address>
        <city>Northbrook</city>
        <state>Illinois</state>
        <zip>60062</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997 Jul;36(7):980-8.</citation>
    <PMID>9204677</PMID>
  </reference>
  <reference>
    <citation>Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R. Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry. 2006 Apr;45(4):415-21.</citation>
    <PMID>16601646</PMID>
  </reference>
  <reference>
    <citation>Schachar R, Jadad AR, Gauld M, Boyle M, Booker L, Snider A, Kim M, Cunningham C. Attention-deficit hyperactivity disorder: critical appraisal of extended treatment studies. Can J Psychiatry. 2002 May;47(4):337-48.</citation>
    <PMID>12025432</PMID>
  </reference>
  <reference>
    <citation>Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM, Onyango AN, Forehand G, Nguyen A, Waxmonsky J. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics. 1999 Apr;103(4):e43.</citation>
    <PMID>10103335</PMID>
  </reference>
  <reference>
    <citation>Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH. A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 2003 Nov;112(5):e404.</citation>
    <PMID>14595084</PMID>
  </reference>
  <results_reference>
    <citation>Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, Newcorn JH. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011 Dec;21(6):581-8. doi: 10.1089/cap.2011.0018. Epub 2011 Dec 2.</citation>
    <PMID>22136094</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <results_first_submitted>December 16, 2015</results_first_submitted>
  <results_first_submitted_qc>March 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2017</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Mark Stein</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Attention Deficit Hyperactivity Disorder</keyword>
  <keyword>sleep</keyword>
  <keyword>side effects</keyword>
  <keyword>stimulants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Adderall</mesh_term>
    <mesh_term>Dexmethylphenidate Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Eligible participants were recruited from the investigators' practices, clinic referrals, and radio advertisements. Participants were enrolled between January 2007 and January 2009.</recruitment_details>
      <pre_assignment_details>7 participants didn't want to participate after screening, 1 didn't meet criteria, 1 ADHD was not the primary condition, 1 showed an abnormal lab/physical/EKG, 1 was unable to swallow pills, 1 had an exclusionary medical condition, 1 was removed due to protocol violations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Focalin XR Then Adderall XR</title>
          <description>Focalin XR first for 4 weeks (3 dose levels and placebo) then Adderall XR for 4 weeks (3 dose levels and placebo).</description>
        </group>
        <group group_id="P2">
          <title>Adderall XR Then Focalin XR</title>
          <description>Adderall XR first for 4 weeks (3 dose levels and placebo) then Focalin XR for 4 weeks (3 dose levels and placebo).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed the Placebo Dosage</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 10mg Dosage</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 20 mg Dosage</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 25/30mg Dosage</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervetion</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Placebo Dosage</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 10 mg Dosage</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed the 20mg Dosage</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed 25/30 mg Dosage</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>77 individuals were screened , 13 patients were excluded, 64 patients were randomized. Of the 64 randomized, 21 discontinued at various points during the trial.</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Participants either Adderall XR or Focalin XR for four weeks (3 dose levels and placebo) followed by four weeks (3 dose levels and placebo) of the opposite medication they received the first four weeks. Baseline Measures are based off all participants that were randomized regardless of the order they received the medication. Since we were interested in evaluating efficacy and adverse events at all dose conditions, participants were included in analysis if they received at least 2 weeks of study drug to insure that all participants had been exposed to at least one week of active drug</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.7" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sleep Start Time, and End Time as Determined by Actigraph and Sleep Diary Over 8 Weeks.</title>
        <description>Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep. The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep.</description>
        <time_frame>8-10 weeks</time_frame>
        <population>Subjects with complete and valid actigraphy (n = 37) and sleep diaries were used to calculate sleep onset latency and sleep duration.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Regardless of the medication the participants were taking, each 4 week period included a randomized placebo week. This data is based off each participant's placebo weeks.</description>
          </group>
          <group group_id="O2">
            <title>10mg of Either Focalin XR or Adderall XR</title>
            <description>Each participant received 10mg of either Focalin XR or Adderall XR. The data collected from the 10mg week of both drugs was combined.</description>
          </group>
          <group group_id="O3">
            <title>20mg of Either Focalin XR or Adderall XR</title>
            <description>Each participant received 20mg of either Focalin XR or Adderall XR. The data collected from the 20mg week of both drugs was combined.</description>
          </group>
          <group group_id="O4">
            <title>25/30mg of Either Focalin XR or Adderall XR</title>
            <description>Each participant received 25 or 30mg of either Focalin XR or Adderall XR depending on their weight. The data collected from the 25/30mg week of both drugs was combined.</description>
          </group>
          <group group_id="O5">
            <title>Adderall XR All Dose Levels</title>
            <description>Participants were given 10mg, 20mg, 25/30mg (depending on their weight) and a randomized placebo week for 4 weeks. This data is combines the 10mg, 20mg, and 25/30mg data for Adderall XR.</description>
          </group>
          <group group_id="O6">
            <title>Focalin XR All Dose Levels</title>
            <description>Participants were given 10mg, 20mg, 25/30mg (depending on their weight) and a randomized placebo week for 4 weeks. This data is combines the 10mg, 20mg, and 25/30mg data for Focalin XR.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Start Time, and End Time as Determined by Actigraph and Sleep Diary Over 8 Weeks.</title>
          <description>Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep. The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep.</description>
          <population>Subjects with complete and valid actigraphy (n = 37) and sleep diaries were used to calculate sleep onset latency and sleep duration.</population>
          <units>HHMM.SS</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sleep start time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2249" spread="0012.19"/>
                    <measurement group_id="O2" value="2304" spread="0010.40"/>
                    <measurement group_id="O3" value="2319" spread="0012.21"/>
                    <measurement group_id="O4" value="2325" spread="0011.17"/>
                    <measurement group_id="O5" value="2309" spread="0011.05"/>
                    <measurement group_id="O6" value="2309" spread="0011.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sleep End time</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0742" spread="0015.36"/>
                    <measurement group_id="O2" value="0728" spread="0009.54"/>
                    <measurement group_id="O3" value="0735" spread="0010.46"/>
                    <measurement group_id="O4" value="0732" spread="0011.09"/>
                    <measurement group_id="O5" value="0735" spread="0010.40"/>
                    <measurement group_id="O6" value="0734" spread="0010.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sleep Duration</title>
        <description>Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep.The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep.</description>
        <time_frame>8-10 weeks</time_frame>
        <population>participants with sufficient sleep actigraphy data for analysis (n=37)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Regardless of the medication the participants were taking, each 4 week period included a randomized placebo week. This data is based off each participant's placebo weeks.</description>
          </group>
          <group group_id="O2">
            <title>10mg of Either Focalin XR or Adderall XR</title>
            <description>Each participant received 10mg of either Focalin XR or Adderall XR. The data collected from the 10mg week of both drugs was combined.</description>
          </group>
          <group group_id="O3">
            <title>20 mg of Either Focalin XR or Adderall XR</title>
            <description>Each participant received 20mg of either Focalin XR or Adderall XR. The data collected from the 20mg week of both drugs was combined.</description>
          </group>
          <group group_id="O4">
            <title>25/30mg of Either Focalin XR or Adderall XR</title>
            <description>Each participant received 25/30mg of either Focalin XR or Adderall XR depending on their weight. The data collected from the 25/30mg week of both drugs was combined.</description>
          </group>
          <group group_id="O5">
            <title>Adderall XR All Dose Levels</title>
            <description>Participants were given 10mg, 20mg, 25/30mg (depending on their weight) and a randomized placebo week for 4 weeks. This data is combines the 10mg, 20mg, and 25/30mg data for Adderall XR.</description>
          </group>
          <group group_id="O6">
            <title>Focalin XR All Dose Levels</title>
            <description>Participants were given 10mg, 20mg, 25/30mg (depending on their weight) and a randomized placebo week for 4 weeks. This data is combines the 10mg, 20mg, and 25/30mg data for Focalin XR.</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Duration</title>
          <description>Actigraphs (AW64 series) were worn each night and were used to assess participant's sleep patterns in their natural home environment. These computerized wristwatch-like devices collect data generated by movements. They are minimally invasive and allow sleep to be recorded reliably without interfering with the family's routine. One-minute epochs were used to analyze actigraphic sleep sata. Bedtimes and wake times were reported for each participant using sleep logs, and these times were used as the start and end times for the analyses. For each 1-min epoch, the total sum of activity counts were computed. If they exceeded a threshold (threshold sensitivity value = mean score in active period/45), then the epoch was considered waking. If it fell below that threshold, then it was considered sleep.The data for Adderall XR and Focalin XR was combined to look at the cumulative effects that medication has on sleep.</description>
          <population>participants with sufficient sleep actigraphy data for analysis (n=37)</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="37"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="37"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="459.6" spread="73.6"/>
                    <measurement group_id="O2" value="446.7" spread="63.58"/>
                    <measurement group_id="O3" value="432.17" spread="64.6"/>
                    <measurement group_id="O4" value="425.5" spread="61.5"/>
                    <measurement group_id="O5" value="438.82" spread="67.2"/>
                    <measurement group_id="O6" value="443.2" spread="66.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ADHD Parent Rating Scale-IV</title>
        <description>Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms.</description>
        <time_frame>completed weekly over 8-10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR - Placebo</title>
            <description>This is the placebo dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O2">
            <title>Adderall XR - 10 mg</title>
            <description>This is the 10 mg dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O3">
            <title>Adderall XR - 20 mg</title>
            <description>This is the 20 mg dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O4">
            <title>Adderall XR - 25/30mg</title>
            <description>This is the 25/30 mg dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O5">
            <title>Focalin XR - Placebo</title>
            <description>This is the placebo dosage week for the Focalin XR medication.</description>
          </group>
          <group group_id="O6">
            <title>Focalin XR - 10 mg</title>
            <description>This is the 10 mg dosage week for the Focalin XR medication.</description>
          </group>
          <group group_id="O7">
            <title>Focalin XR - 20 mg</title>
            <description>This is the 20 mg dosage week for the Focalin XR medication.</description>
          </group>
          <group group_id="O8">
            <title>Focalin XR - 25/30mg</title>
            <description>This is the 25/30 mg dosage week for the Focalin XR medication.</description>
          </group>
        </group_list>
        <measure>
          <title>ADHD Parent Rating Scale-IV</title>
          <description>Measures the severity of Total ADHD symptoms, Inattention and Hyperactivity/Impulsive symptoms. The Inattention and Hyperactivity/Impulsive symptoms can range from 0 to 27 each, with a higher score reflecting more severe ADHD symptoms. The total score is calculated by summing the inattention and Hyperactivity/Impulsive subscales. The total score can range from 0 to 54 with a higher score reflecting more severe ADHD symptoms.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="47"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="55"/>
                <count group_id="O7" value="52"/>
                <count group_id="O8" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Inattention Symptom Subscale Scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.61" spread="7.8"/>
                    <measurement group_id="O2" value="6.40" spread="8.55"/>
                    <measurement group_id="O3" value="12.2" spread="8.08"/>
                    <measurement group_id="O4" value="12.74" spread="8.38"/>
                    <measurement group_id="O5" value="17.31" spread="8.23"/>
                    <measurement group_id="O6" value="17.51" spread="7.03"/>
                    <measurement group_id="O7" value="13.33" spread="7.08"/>
                    <measurement group_id="O8" value="12.11" spread="8.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperactivity/Impulsivity Symptom subscale scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.41" spread="8.55"/>
                    <measurement group_id="O2" value="10.78" spread="7.60"/>
                    <measurement group_id="O3" value="7.92" spread="6.78"/>
                    <measurement group_id="O4" value="7.67" spread="6.62"/>
                    <measurement group_id="O5" value="13.24" spread="8.91"/>
                    <measurement group_id="O6" value="10.84" spread="7.37"/>
                    <measurement group_id="O7" value="8.49" spread="7.37"/>
                    <measurement group_id="O8" value="8.49" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Symptoms scores</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.02" spread="15.15"/>
                    <measurement group_id="O2" value="27.15" spread="14.49"/>
                    <measurement group_id="O3" value="20.12" spread="13.87"/>
                    <measurement group_id="O4" value="20.40" spread="13.68"/>
                    <measurement group_id="O5" value="30.58" spread="15.33"/>
                    <measurement group_id="O6" value="28.35" spread="12.74"/>
                    <measurement group_id="O7" value="21.82" spread="12.72"/>
                    <measurement group_id="O8" value="20.41" spread="13.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dopamine Active Transporter (DAT) 1 Gene Type Effects on ADHD Symptoms</title>
        <description>Three variations of the DAT 1 gene were observed, the 9/9 allele, the 9/10 allele and the 10/10 allele. The ADHD Rating Scale (ADHD-RS) and Clinical Global Impressions - Severity (CGI-S) measures were used to evaluate how the DAT 1 gene allele type altered the efficacy of the medication. The DAT 1 genotype did not predict differential response to Focalin XR or Adderall XR so the dose levels of each drug was combined to examine how the genotype interacted with the dose level. The ADHD-RS evaluates the severity of the participant's ADHD symptoms and includes two subscales: Inattention and Hyperactivity/Impulsivity. Both subscale scores range from 0 to 27 with a higher score representing more severe symptoms. The subscales are summed to calculate the total score which can range from 0 to 54. The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill.</description>
        <time_frame>8-10 weeks</time_frame>
        <population>The number of participants analyzed differs from the participant flow because some participants refused to provide a DNA sample for analysis or some participants did not have the allele type that was being observed. Of those that provided a DNA sample, 6 had the 9/9 allele on the DAT 1 gene, 15 had the 9/10 allele and 30 had the 10/10 allele.</population>
        <group_list>
          <group group_id="O1">
            <title>9/9 Allele: Placebo of Adderall XR</title>
            <description>This is the Placebo dosage of Adderall XR medication phase for the participants with the 9/9 allele</description>
          </group>
          <group group_id="O2">
            <title>9/9 Allele: 10 mg of Adderall XR</title>
            <description>This is the 10 mg dosage of Adderall XR medication phase for the participants with the 9/9 allele</description>
          </group>
          <group group_id="O3">
            <title>9/9 Allele: 20 mg Adderall XR</title>
            <description>This is the 20 mg dosage of Adderall XR medication phase for the participants with the 9/9 allele</description>
          </group>
          <group group_id="O4">
            <title>9/9 Allele: 25/30mg of Adderall XR</title>
            <description>This is the 25/30 mg dosage of Adderall XR medication phase for the participants with the 9/9 allele</description>
          </group>
          <group group_id="O5">
            <title>9/9 Allele: Placebo of Focalin XR</title>
            <description>This is the placebo dosage of Focalin XR medication phase for the participants with the 9/9 allele</description>
          </group>
          <group group_id="O6">
            <title>9/9 Allele: 10 mg of Focalin XR</title>
            <description>This is the 10 mg dosage of Focalin XR medication phase for the participants with the 9/9 allele</description>
          </group>
          <group group_id="O7">
            <title>9/9 Allele: 20 mg of Focalin XR</title>
            <description>This is the 20 mg dosage of Focalin XR medication phase for the participants with the 9/9 allele</description>
          </group>
          <group group_id="O8">
            <title>9/9 Allele: 25/30 mg of Focalin XR</title>
            <description>This is the 25/30 mg dosage of Focalin XR medication phase for the participants with the 9/9 allele</description>
          </group>
          <group group_id="O9">
            <title>9/10 Allele: Placebo of Adderall XR</title>
            <description>This is the Placebo dosage of Adderall XR medication phase for the participants with the 9/10 allele</description>
          </group>
          <group group_id="O10">
            <title>9/10 Allele: 10 mg of Adderall XR</title>
            <description>This is the 10 mg dosage of Adderall XR medication phase for the participants with the 9/10 allele</description>
          </group>
          <group group_id="O11">
            <title>9/10 Allele: 20 mg of Adderall XR</title>
            <description>This is the 20 mg dosage of Adderall XR medication phase for the participants with the 9/10 allele</description>
          </group>
          <group group_id="O12">
            <title>9/10 Allele: 25/30 mg of Adderall XR</title>
            <description>This is the 25/30 mg dosage of Adderall XR medication phase for the participants with the 9/10 allele</description>
          </group>
          <group group_id="O13">
            <title>9/10 Allele: Placebo of Focalin XR</title>
            <description>This is the Placebo dosage of Focalin XR medication phase for the participants with the 9/10 allele</description>
          </group>
          <group group_id="O14">
            <title>9/10 Allele: 10 mg of Focalin XR</title>
            <description>This is the 10 mg dosage of Focalin XR medication phase for the participants with the 9/10 allele</description>
          </group>
          <group group_id="O15">
            <title>9/10 Allele: 20 mg of Focalin XR</title>
            <description>This is the 20 mg dosage of Focalin XR medication phase for the participants with the 9/10 allele</description>
          </group>
          <group group_id="O16">
            <title>9/10 Allele: 25/30 mg of Focalin XR</title>
            <description>This is the 25/30 mg dosage of Focalin XR medication phase for the participants with the 9/10 allele</description>
          </group>
          <group group_id="O17">
            <title>10/10 Allele: Placebo of Adderall XR</title>
            <description>This is the Placebo dosage of Adderall XR medication phase for the participants with the 10/10 allele</description>
          </group>
          <group group_id="O18">
            <title>10/10 Allele: 10 mg of Adderall XR</title>
            <description>This is the 10 mg dosage of Adderall XR medication phase for the participants with the 10/10 allele</description>
          </group>
          <group group_id="O19">
            <title>10/10 Allele: 20 mg of Adderall XR</title>
            <description>This is the 20 mg dosage of Adderall XR medication phase for the participants with the 10/10 allele</description>
          </group>
          <group group_id="O20">
            <title>10/10 Allele: 25/30 mg of Adderall XR</title>
            <description>This is the 25/30 mg dosage of Adderall XR medication phase for the participants with the 10/10 allele</description>
          </group>
          <group group_id="O21">
            <title>10/10 Allele: Placebo of Focalin XR</title>
            <description>This is the Placebo dosage of Focalin XR medication phase for the participants with the 10/10 allele</description>
          </group>
          <group group_id="O22">
            <title>10/10 Allele: 10 mg of Focalin XR</title>
            <description>This is the 10 mg dosage of Focalin XR medication phase for the participants with the 10/10 allele</description>
          </group>
          <group group_id="O23">
            <title>10/10 Allele: 20 mg of Focalin XR</title>
            <description>This is the 20 mg dosage of Focalin XR medication phase for the participants with the 10/10 allele</description>
          </group>
          <group group_id="O24">
            <title>10/10 Allele: 25/30mg of Focaling XR</title>
            <description>This is the 25/30 mg dosage of Focalin XR medication phase for the participants with the 10/10 allele</description>
          </group>
        </group_list>
        <measure>
          <title>Dopamine Active Transporter (DAT) 1 Gene Type Effects on ADHD Symptoms</title>
          <description>Three variations of the DAT 1 gene were observed, the 9/9 allele, the 9/10 allele and the 10/10 allele. The ADHD Rating Scale (ADHD-RS) and Clinical Global Impressions - Severity (CGI-S) measures were used to evaluate how the DAT 1 gene allele type altered the efficacy of the medication. The DAT 1 genotype did not predict differential response to Focalin XR or Adderall XR so the dose levels of each drug was combined to examine how the genotype interacted with the dose level. The ADHD-RS evaluates the severity of the participant's ADHD symptoms and includes two subscales: Inattention and Hyperactivity/Impulsivity. Both subscale scores range from 0 to 27 with a higher score representing more severe symptoms. The subscales are summed to calculate the total score which can range from 0 to 54. The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill.</description>
          <population>The number of participants analyzed differs from the participant flow because some participants refused to provide a DNA sample for analysis or some participants did not have the allele type that was being observed. Of those that provided a DNA sample, 6 had the 9/9 allele on the DAT 1 gene, 15 had the 9/10 allele and 30 had the 10/10 allele.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="5"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="4"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="14"/>
                <count group_id="O10" value="15"/>
                <count group_id="O11" value="14"/>
                <count group_id="O12" value="14"/>
                <count group_id="O13" value="13"/>
                <count group_id="O14" value="15"/>
                <count group_id="O15" value="12"/>
                <count group_id="O16" value="10"/>
                <count group_id="O17" value="30"/>
                <count group_id="O18" value="30"/>
                <count group_id="O19" value="29"/>
                <count group_id="O20" value="26"/>
                <count group_id="O21" value="27"/>
                <count group_id="O22" value="27"/>
                <count group_id="O23" value="27"/>
                <count group_id="O24" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADHD-RS Inattention subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.60" spread="9.61"/>
                    <measurement group_id="O2" value="18.83" spread="10.59"/>
                    <measurement group_id="O3" value="19.00" spread="8.51"/>
                    <measurement group_id="O4" value="15.40" spread="9.18"/>
                    <measurement group_id="O5" value="19.33" spread="7.51"/>
                    <measurement group_id="O6" value="22.20" spread="4.76"/>
                    <measurement group_id="O7" value="16.75" spread="8.81"/>
                    <measurement group_id="O8" value="12.50" spread="9.81"/>
                    <measurement group_id="O9" value="18.64" spread="6.55"/>
                    <measurement group_id="O10" value="16.27" spread="7.33"/>
                    <measurement group_id="O11" value="15.86" spread="6.71"/>
                    <measurement group_id="O12" value="13.43" spread="7.95"/>
                    <measurement group_id="O13" value="18.08" spread="8.51"/>
                    <measurement group_id="O14" value="16.93" spread="5.59"/>
                    <measurement group_id="O15" value="13.36" spread="8.27"/>
                    <measurement group_id="O16" value="13.70" spread="9.86"/>
                    <measurement group_id="O17" value="15.07" spread="8.14"/>
                    <measurement group_id="O18" value="16.13" spread="9.35"/>
                    <measurement group_id="O19" value="9.36" spread="7.88"/>
                    <measurement group_id="O20" value="11.96" spread="8.65"/>
                    <measurement group_id="O21" value="16.44" spread="8.44"/>
                    <measurement group_id="O22" value="16.56" spread="7.92"/>
                    <measurement group_id="O23" value="12.56" spread="6.64"/>
                    <measurement group_id="O24" value="11.15" spread="8.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADHD-RS Hyperactivity/Impulsivity subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.80" spread="8.90"/>
                    <measurement group_id="O2" value="18.33" spread="10.03"/>
                    <measurement group_id="O3" value="14.80" spread="8.07"/>
                    <measurement group_id="O4" value="10.40" spread="9.96"/>
                    <measurement group_id="O5" value="17.33" spread="2.52"/>
                    <measurement group_id="O6" value="17.40" spread="4.77"/>
                    <measurement group_id="O7" value="14.00" spread="9.13"/>
                    <measurement group_id="O8" value="9.00" spread="7.07"/>
                    <measurement group_id="O9" value="9.36" spread="8.95"/>
                    <measurement group_id="O10" value="10.67" spread="7.74"/>
                    <measurement group_id="O11" value="8.36" spread="7.04"/>
                    <measurement group_id="O12" value="6.43" spread="6.95"/>
                    <measurement group_id="O13" value="8.92" spread="9.38"/>
                    <measurement group_id="O14" value="8.27" spread="7.23"/>
                    <measurement group_id="O15" value="6.73" spread="7.04"/>
                    <measurement group_id="O16" value="7.00" spread="7.02"/>
                    <measurement group_id="O17" value="11.87" spread="8.76"/>
                    <measurement group_id="O18" value="9.63" spread="6.83"/>
                    <measurement group_id="O19" value="7.07" spread="6.18"/>
                    <measurement group_id="O20" value="7.50" spread="5.70"/>
                    <measurement group_id="O21" value="13.74" spread="9.19"/>
                    <measurement group_id="O22" value="10.63" spread="7.14"/>
                    <measurement group_id="O23" value="8.41" spread="6.34"/>
                    <measurement group_id="O24" value="8.65" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADHD-RS total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.40" spread="18.06"/>
                    <measurement group_id="O2" value="37.17" spread="20.55"/>
                    <measurement group_id="O3" value="33.80" spread="16.33"/>
                    <measurement group_id="O4" value="25.80" spread="19.03"/>
                    <measurement group_id="O5" value="36.67" spread="6.43"/>
                    <measurement group_id="O6" value="39.60" spread="8.44"/>
                    <measurement group_id="O7" value="30.75" spread="17.63"/>
                    <measurement group_id="O8" value="24.00" spread="17.19"/>
                    <measurement group_id="O9" value="28.00" spread="13.59"/>
                    <measurement group_id="O10" value="26.80" spread="13.14"/>
                    <measurement group_id="O11" value="24.21" spread="13.01"/>
                    <measurement group_id="O12" value="19.86" spread="12.84"/>
                    <measurement group_id="O13" value="27.08" spread="15.71"/>
                    <measurement group_id="O14" value="25.20" spread="11.89"/>
                    <measurement group_id="O15" value="20.09" spread="13.71"/>
                    <measurement group_id="O16" value="20.70" spread="15.84"/>
                    <measurement group_id="O17" value="26.93" spread="16.05"/>
                    <measurement group_id="O18" value="25.77" spread="14.33"/>
                    <measurement group_id="O19" value="16.43" spread="13.01"/>
                    <measurement group_id="O20" value="19.46" spread="13.20"/>
                    <measurement group_id="O21" value="30.19" spread="16.49"/>
                    <measurement group_id="O22" value="27.19" spread="12.93"/>
                    <measurement group_id="O23" value="20.96" spread="11.98"/>
                    <measurement group_id="O24" value="19.81" spread="13.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CGI-S score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" spread="0.55"/>
                    <measurement group_id="O2" value="4.33" spread="1.51"/>
                    <measurement group_id="O3" value="4.80" spread="1.30"/>
                    <measurement group_id="O4" value="4.00" spread="1.58"/>
                    <measurement group_id="O5" value="4.67" spread="0.58"/>
                    <measurement group_id="O6" value="4.60" spread="0.55"/>
                    <measurement group_id="O7" value="4.50" spread="1.29"/>
                    <measurement group_id="O8" value="4.00" spread="1.63"/>
                    <measurement group_id="O9" value="4.36" spread="1.08"/>
                    <measurement group_id="O10" value="4.07" spread="1.03"/>
                    <measurement group_id="O11" value="3.71" spread="1.14"/>
                    <measurement group_id="O12" value="3.50" spread="1.40"/>
                    <measurement group_id="O13" value="4.31" spread="0.95"/>
                    <measurement group_id="O14" value="4.27" spread="0.70"/>
                    <measurement group_id="O15" value="3.58" spread="1.38"/>
                    <measurement group_id="O16" value="3.90" spread="1.66"/>
                    <measurement group_id="O17" value="4.17" spread="1.39"/>
                    <measurement group_id="O18" value="4.07" spread="1.48"/>
                    <measurement group_id="O19" value="3.21" spread="1.32"/>
                    <measurement group_id="O20" value="3.54" spread="1.24"/>
                    <measurement group_id="O21" value="4.15" spread="1.29"/>
                    <measurement group_id="O22" value="4.19" spread="0.83"/>
                    <measurement group_id="O23" value="3.52" spread="1.12"/>
                    <measurement group_id="O24" value="3.31" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Global Impression - Severity</title>
        <description>The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill.</description>
        <time_frame>8-10 weeks</time_frame>
        <population>The number of participants analyzed differs from the participant flow in the Focalin XR groups because the CGI-S was not completed for every participant. The same is true for the Adderall XR - 25/30mg group.</population>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR - Placebo</title>
            <description>This is the placebo dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O2">
            <title>Adderall XR - 10 mg</title>
            <description>This is the 10 mg dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O3">
            <title>Adderall XR - 20 mg</title>
            <description>This is the 20 mg dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O4">
            <title>Adderall XR - 25/30 mg</title>
            <description>This is the 25/30 mg dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O5">
            <title>Focalin XR - Placebo</title>
            <description>This is the placebo dosage week for the Focalin XR medication.</description>
          </group>
          <group group_id="O6">
            <title>Focalin - 10 mg</title>
            <description>This is the 10 mg dosage week for the Focalin XR medication.</description>
          </group>
          <group group_id="O7">
            <title>Focalin XR - 20 mg</title>
            <description>This is the 20 mg dosage week for the Focalin XR medication.</description>
          </group>
          <group group_id="O8">
            <title>Focalin XR - 25/30 mg</title>
            <description>This is the 25/30 mg dosage week for the Focalin XR medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Global Impression - Severity</title>
          <description>The CGI-S scale summarizes the clinician's impression of the participant's symptom severity and ranges from 1-7 with 1 representing normal (not at all ill) and 7 representing extremely ill.</description>
          <population>The number of participants analyzed differs from the participant flow in the Focalin XR groups because the CGI-S was not completed for every participant. The same is true for the Adderall XR - 25/30mg group.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="48"/>
                <count group_id="O5" value="45"/>
                <count group_id="O6" value="51"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="1.18"/>
                    <measurement group_id="O2" value="4.09" spread="1.29"/>
                    <measurement group_id="O3" value="3.48" spread="1.34"/>
                    <measurement group_id="O4" value="3.56" spread="1.27"/>
                    <measurement group_id="O5" value="4.24" spread="1.13"/>
                    <measurement group_id="O6" value="4.24" spread="0.76"/>
                    <measurement group_id="O7" value="3.63" spread="1.20"/>
                    <measurement group_id="O8" value="3.55" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weiss Functional Impairment Rating Scale (WFIRS)</title>
        <description>The WFIRS consists of 50 questions where respondents are asked to rate their child's functional impairment. The items of the WFIRS are scored on a four point Likert-type rating scale: 0 (never or not at all), 1 (sometimes or somewhat), 2 (often or much) or 3 (very often or very much) and aggregated to produce six domain scores: Family (ranges between 0-24), Learning or School (ranges between 0-33), Self-Concept (ranges between 0-15), Social Activities (ranges between 0-27), Life Skills (ranges between 0-36), and Risky Activities (ranges between 0-42). The subscales are scored by summing the responses in the subsection. The Total score is the sum of all the responses and it ranges between 0-150. The higher the score in each of the subscales the more impairment is recorded, this is also true for the total score.</description>
        <time_frame>8-10 weeks</time_frame>
        <population>The number of participants analyzed differs from the participant flow in all of the groups besides the Adderall XR - 10mg group because the WFIRS was not completed for every participant.</population>
        <group_list>
          <group group_id="O1">
            <title>Adderall XR - Placebo</title>
            <description>This is the placebo dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O2">
            <title>Adderall XR - 10 mg</title>
            <description>This is the 10 mg dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O3">
            <title>Adderall XR - 20 mg</title>
            <description>This is the 20 mg dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O4">
            <title>Adderall XR - 25/30mg</title>
            <description>This is the 25/30 mg dosage week for the Adderall XR medication.</description>
          </group>
          <group group_id="O5">
            <title>Focalin XR - Placebo</title>
            <description>This is the Placebo dosage week for the Focalin XR medication.</description>
          </group>
          <group group_id="O6">
            <title>Focalin XR - 10 mg</title>
            <description>This is the 10 mg dosage week for the Focalin XR medication.</description>
          </group>
          <group group_id="O7">
            <title>Focalin XR - 20 mg</title>
            <description>This is the 20 mg dosage week for the Focalin XR medication.</description>
          </group>
          <group group_id="O8">
            <title>Focalin XR - 25/30mg</title>
            <description>This is the 25/30 mg dosage week for the Focalin XR medication.</description>
          </group>
        </group_list>
        <measure>
          <title>Weiss Functional Impairment Rating Scale (WFIRS)</title>
          <description>The WFIRS consists of 50 questions where respondents are asked to rate their child's functional impairment. The items of the WFIRS are scored on a four point Likert-type rating scale: 0 (never or not at all), 1 (sometimes or somewhat), 2 (often or much) or 3 (very often or very much) and aggregated to produce six domain scores: Family (ranges between 0-24), Learning or School (ranges between 0-33), Self-Concept (ranges between 0-15), Social Activities (ranges between 0-27), Life Skills (ranges between 0-36), and Risky Activities (ranges between 0-42). The subscales are scored by summing the responses in the subsection. The Total score is the sum of all the responses and it ranges between 0-150. The higher the score in each of the subscales the more impairment is recorded, this is also true for the total score.</description>
          <population>The number of participants analyzed differs from the participant flow in all of the groups besides the Adderall XR - 10mg group because the WFIRS was not completed for every participant.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="55"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="47"/>
                <count group_id="O5" value="44"/>
                <count group_id="O6" value="48"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Family subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.72" spread="6.13"/>
                    <measurement group_id="O2" value="7.02" spread="6.41"/>
                    <measurement group_id="O3" value="6.35" spread="6.10"/>
                    <measurement group_id="O4" value="6.70" spread="7.14"/>
                    <measurement group_id="O5" value="7.39" spread="7.14"/>
                    <measurement group_id="O6" value="7.35" spread="6.09"/>
                    <measurement group_id="O7" value="6.50" spread="6.42"/>
                    <measurement group_id="O8" value="6.50" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Learning subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.74" spread="5.63"/>
                    <measurement group_id="O2" value="8.75" spread="6.70"/>
                    <measurement group_id="O3" value="6.86" spread="6.19"/>
                    <measurement group_id="O4" value="6.21" spread="5.62"/>
                    <measurement group_id="O5" value="9.30" spread="6.34"/>
                    <measurement group_id="O6" value="9.25" spread="5.94"/>
                    <measurement group_id="O7" value="7.54" spread="5.24"/>
                    <measurement group_id="O8" value="7.39" spread="5.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life skills subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.43" spread="4.32"/>
                    <measurement group_id="O2" value="7.91" spread="4.78"/>
                    <measurement group_id="O3" value="7.44" spread="4.99"/>
                    <measurement group_id="O4" value="7.34" spread="4.45"/>
                    <measurement group_id="O5" value="8.30" spread="4.76"/>
                    <measurement group_id="O6" value="7.65" spread="4.44"/>
                    <measurement group_id="O7" value="8.30" spread="5.48"/>
                    <measurement group_id="O8" value="7.60" spread="5.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-concept subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="1.46"/>
                    <measurement group_id="O2" value="1.59" spread="2.05"/>
                    <measurement group_id="O3" value="1.42" spread="1.80"/>
                    <measurement group_id="O4" value="1.06" spread="1.61"/>
                    <measurement group_id="O5" value="1.25" spread="1.97"/>
                    <measurement group_id="O6" value="1.19" spread="1.47"/>
                    <measurement group_id="O7" value="1.33" spread="1.61"/>
                    <measurement group_id="O8" value="1.31" spread="1.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Social activities subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.51" spread="3.53"/>
                    <measurement group_id="O2" value="3.91" spread="3.81"/>
                    <measurement group_id="O3" value="2.98" spread="3.10"/>
                    <measurement group_id="O4" value="3.06" spread="4.05"/>
                    <measurement group_id="O5" value="3.73" spread="4.14"/>
                    <measurement group_id="O6" value="3.85" spread="3.57"/>
                    <measurement group_id="O7" value="3.54" spread="3.40"/>
                    <measurement group_id="O8" value="3.17" spread="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Risky activities subscale score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" spread="2.56"/>
                    <measurement group_id="O2" value="1.94" spread="2.30"/>
                    <measurement group_id="O3" value="2.24" spread="3.41"/>
                    <measurement group_id="O4" value="1.68" spread="2.23"/>
                    <measurement group_id="O5" value="1.91" spread="1.64"/>
                    <measurement group_id="O6" value="1.96" spread="2.12"/>
                    <measurement group_id="O7" value="1.78" spread="1.78"/>
                    <measurement group_id="O8" value="1.67" spread="1.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.70" spread="17.03"/>
                    <measurement group_id="O2" value="31.06" spread="18.93"/>
                    <measurement group_id="O3" value="27.32" spread="19.53"/>
                    <measurement group_id="O4" value="26.23" spread="19.74"/>
                    <measurement group_id="O5" value="20.91" spread="17.50"/>
                    <measurement group_id="O6" value="31.13" spread="17.11"/>
                    <measurement group_id="O7" value="29.20" spread="17.71"/>
                    <measurement group_id="O8" value="27.45" spread="18.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8-10 weeks. Adverse events were collected from participants while they were in the study, this time frame ranged from 8-10 weeks.</time_frame>
      <desc>At each weekly visit, children and their parents met with the investigators and research staff. Parents completed the Stimulant Side Effects Rating scale (SERS), a 17-item scale that is rated on a 10-point (0-9) scale ranging from absent to serious.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo of Focalin XR</title>
          <description>Each participant recieved placebo of Focalin XR once during the first four weeks or last four weeks depending on the randomization schedule.</description>
        </group>
        <group group_id="E2">
          <title>10mg of Focalin XR</title>
          <description>Each participant recieved 10 mg of Focalin XR once during the first four weeks or last four weeks depending on the randomization schedule.</description>
        </group>
        <group group_id="E3">
          <title>20 mg of Focalin XR</title>
          <description>Each participant recieved 20 mg of Focalin XR once during the first four weeks or last four weeks depending on the randomization schedule.</description>
        </group>
        <group group_id="E4">
          <title>25/30mg of Focalin XR</title>
          <description>Each participant recieved 25/30 mg (depending on weight) of Focalin XR once during the first four weeks or last four weeks depending on the randomization schedule.</description>
        </group>
        <group group_id="E5">
          <title>Placebo of Adderall XR</title>
          <description>Each participant recieved placebo of Adderall XR once during the first four weeks or last four weeks depending on the randomization schedule.</description>
        </group>
        <group group_id="E6">
          <title>10mg of Adderall XR</title>
          <description>Each participant recieved 10 mg of Adderall XR once during the first four weeks or last four weeks depending on the randomization schedule.</description>
        </group>
        <group group_id="E7">
          <title>20 mg of Adderall XR</title>
          <description>Each participant recieved 20 mg of Adderall XR once during the first four weeks or last four weeks depending on the randomization schedule.</description>
        </group>
        <group group_id="E8">
          <title>25/30mg of Adderall XR</title>
          <description>Each participant recieved 25/30 mg of Adderall XR once during the first four weeks or last four weeks depending on the randomization schedule.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SERS</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Subject shaking in bed,unresponsive,eyes rolled upward. Taken to ER. ECG showed possible prolonged QTc. Subject evaluated overnight. No other events. Diagnosed on 12/29 with &quot;benign rolandic seizures.&quot; No further cardiac evaluation recommended.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>SERS</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="32" subjects_at_risk="47"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="47"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="35" subjects_at_risk="55"/>
                <counts group_id="E7" subjects_affected="29" subjects_at_risk="52"/>
                <counts group_id="E8" subjects_affected="31" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach Ache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Talk less</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Irritable</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="47"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="52"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nail biting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="48"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="47"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Stares</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Uninterested</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Sadness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Tics</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of Appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="48"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="47"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E7" events="7" subjects_affected="7" subjects_at_risk="52"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia or trouble sleeping</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="47"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="47"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Euphoric</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="48"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to early withdrawal or loss of contact during the study, the sample size for analysis was smaller.
The dosing design of the study may have led to more adverse events than would occur in clinic.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Mark Stein</name_or_title>
      <organization>Dept. of Psychiatry, University of Washington</organization>
      <phone>206-987-1161</phone>
      <email>mstein42@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

